PANDA-study - Prenatal And Neonatal Development: An offspring study of severe mental illness

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 125

Inclusion Criteria

All pregnant women and their partners:
• At least 18 years old
• Ability to provide informed consent
• Singleton pregnancy
• Biological parent of the fetus/neonate

Pregnant women and their partners with at least one (future) parent with SMI:
• At least one (future) parent with SMI in the mood-psychosis spectrum
diagnosed before current pregnancy, i.e., schizophrenia, bipolar disorder,
severe MDD (i.e., with high recurrence rate and/or hospitalizations), psychosis
NOS, single psychosis < two years ago (not related to drug use; no postpartum
psychosis after a prior pregnancy)

Neonate:
• Born from parents who participated in visit 1 and/or 2 or born from parents
who would have qualified for inclusion in the study (in other words, families
can also only participate in visit 3).

Exclusion Criteria

All pregnant women:
• Contraindication for MRI (including claustrophobia, a cardiac implantable
electronic device, ferromagnetic metal implants, piercing (in some cases),
tattoos (in some cases)) (Ghadimi & Sapra, 2022).
• Postpartum psychosis (after a prior pregnancy)
• Not willing to be informed about incidental findings following MRI assessment

All pregnant women and their partners:
• Substance use disorder (alcohol, drugs), active < six months pre pregnancy as
assessed with R4U or current addiction treatment such as methadone or
buprenorphine
• Not willing to be informed about neonate*s incidental findings following MRI
assessment

All fetuses/neonates:
• Preeclampsia or fetal growth restriction at time of inclusion
• Neurological illness or structural brain abnormalities
• Suspected congenital anomalies or syndromes known to affect neurodevelopment
• Chromosomal abnormalities
• Genetic abnormalities known to impact neurodevelopment
• Premature birth (< 37 weeks)

Pregnant women and their partners without SMI:
• A lifetime diagnosis of SMI in the mood-psychosis spectrum as assessed with
the Structured Clinical Interview for DSM-5 (SCID-5; First, 2014).
• An SMI in the mood-psychosis spectrum in their first degree relatives
• Use of neurotrophic medication

In all (future) parents, (co)morbidity with other psychiatric diagnoses is not
an exclusion criterion.